Dozens of advocacy groups are urging one of the largest American universities not to pursue a patent for a pricey cancer drug in India, opening another front in an ongoing battle over access to the medicine.

At issue is the Xtandi prostate cancer treatment, which was originally invented at the University of California, Los Angeles, and has become a flashpoint in a wider debate in the United States over the extent to which Americans should pay high prices for medicines that were developed, at least in part, with taxpayer dollars.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Amazing what happens when you put a calculator to $44.77 per pill x 4/day … x 365. The cost ends up slightly north of $65,000/ year – what sounded possibly reasonable ends up at just over half of the US price of $129,000/ year. Another flash point where ‘things may get interesting.’

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy